The calcitonin gene-related peptide inhibitor lowered monthly migraine days by ≥50% in 30.3% of patients compared to 13.7% on placebo.
Latest Conference Coverage
Advertisement
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
The Promise and Limitations of Neurofilament Light Chain in Peripheral Nerve Disorders: Brett Morrison, MD, PhD
2
Teva Submits NDA for Ecopipam, Potential First New Tourette Syndrome Treatment in Over a Decade
3
FDA Allows AMT-130 Huntington Disease Data to Support Planned BLA Submission Under Accelerated Approval Pathway
4
Irfan Qureshi, MD, on Opakalim, Kv7 Activation, and the Future of Epilepsy Treatment
5